Introduction
Transforming growth factor-β (TGF-β) is a highly evolutionarily conserved cytokine consisting of three known mammalian family members (TGF-β1, -β2, and -β3) that regulate multiple physiological processes. TGF-β1 is produced by many types of immune cells and nonimmune cells. T cells, T regulatory (Treg) cells, macrophages, effector T cells, and thymic mesenchymal cells and tumor cells are the main sources of TGF-β1 production. As TGF-β1 mainly regulates immune responses and the current review focuses on the immune system, we have used TGF-β to replace TGF-β1 in the review.
TGF-β1 is the predominant isoform expressed in the immune system, and its widespread regulatory activity affects multiple types of immune cells (Li et al., 2006b) . Mice that lack this isoform either die embryonically or, if surviving, develop multiorgan inflammation and die at an early age (Shull et al., 1992) . This phenomenon has highlighted a crucial role for TGF-β in dampening selfharmful inflammatory responses. Nevertheless, TGF-β is more than an immunosuppressive cytokine. For instance, early studies also revealed that TGF-β induces stimulatory or inhibitory effects in human T cells, which depends on the T cell differentiation status and the stimulation conditions (de Jong et al., 1994) . This context-dependent function of TGF-β allows for its distinctive roles in T cell development, homeostasis, tolerance, and differentiation.
TGF-β is synthesized in a latent form that has to be activated via binding to the TGF-β receptor complex. Binding of active TGF-β to its receptor complex triggers receptor serine/threonine kinase activity, allowing for recruitment of the intracellular receptors Smad2 and Smad3 to the cytoplasmic domain of activated TGF-βRI, which directly phosphorylates Smad2/3. Hereafter, Smad2/3 forms a trimeric structure with Smad4, which translocates to the nucleus to activate or repress gene expression via binding to Smad-responsive regulatory regions. Indeed, recent evidence has suggested that, during differentiation of Th17 cells, different isoforms of TGF-β may activate different Smad signaling pathways (Lee et al., 2012) . Hence, it appears that alternative Smad signaling pathways may be initiated by TGF-β in a context-dependent way, although further work is required to determine the biological relevance of differential Smad activation in the regulation of immunity.
In addition, TGF-β can also trigger numerous Smadindependent signaling pathways. For example, signaling via MAP kinases, PI3 kinase, and Rho GTPases all can be triggered by TGF-β receptor engagement (Mu et al., 2012) . Further studies are needed in the field of how and when Smad-dependent and -independent signaling pathways are triggered by TGF-β in immune cells and the relative pleiotropic effects of TGF-β on immune responses.
Function of TGF-β in the development of Treg cells
TGF-β contributes to suppression of T cell-mediated immune responses through either direct or indirect pathway. It is undoubted that TGF-β directly suppresses T cell responses since T cells express TGF-β receptors. A milestone discovery has revealed that TGF-β can induce T suppressor or regulatory cells (Zheng et al., 2002) , and then indirectly clamp down T cells responses (Zheng et al., 2004a (Zheng et al., , 2004b . Treg cells are a subset of T cells that are crucial in maintaining homeostasis via suppression of self-harmful T cell responses (Josefowicz et al., 2012a) . The transcription factor Forkhead box P3, abbreviated as Foxp3, is a specific marker of Treg cells, and its expression is a typical requisite for Treg cell differentiation and function (Hori et al., 2003) . Mice with a mutation in Foxp3 (Brunkow et al., 2001) or with a targeted knockout of Foxp3 in T cells (Fontenot et al., 2005) die of multiorgan inflammation very early in life, akin to mice lacking TGF-β1. Also, humans carrying an inactivating mutation in the FOXP3 gene develop immunodysregulation, endocrinopathy, and enteropathy X-linked (IPEX) syndrome, a severe autoimmune disease generally resulting in death around 2 years of age (van der Vliet and Nieuwenhuis, 2007). There are two major subtypes of Tregs: natural Tregs (nTregs), which are naturally occurring, thymus-derived CD4+CD25+ Treg cells, and induced Tregs (iTregs), which are induced with cytokines TGF-β and IL-2 (Zheng et al., 2002 (Zheng et al., , 2007 . Interestingly, lacking TGF-β does not affect nTreg cell development and function (Piccirillo et al., 2002) , and thus TGF-β appears to play pivotal but different roles in regulating the development of nTreg and iTreg subpopulations.
TGF-β signal and nTreg development
CD4+ and CD8+ T cells can convert to effector T cells conventionally during inflammation and autoimmune responses. Conversely, they can also differentiate to T regulatory cell lineages in the thymus (Kronenberg and Rudensky, 2005) . The development of nTreg cells is determined by the interaction between TCRs and MHC II-self peptide, costimulation, and cytokine signaling pathways (Liston and Rudensky, 2007) . Two studies demonstrated that nTreg numbers were similar (Marie et al., 2006) or increased (Li et al., 2006a) in TGF-βRII T cell-specific deletion mouse models compared with control mice. It is plausible that TGF-β is dispensable to the development of nTreg cells. However, another study with the conditional Tgfr1 gene T cell-specific deletion mouse models demonstrated that TGF-β deficiency hindered nTreg cell differentiation in 3-to 5-day-old mice but touched off nTreg cell expansion in mice 1 week later (Liu et al., 2008) . It needs further study to determine whether or how TGF-β signaling affects nTreg development and expansion in different stages of life.
The nTreg cell proliferation in the later stage can be observed in TGF-βRII-deficient mice (Li et al., 2006b) , and it is postulated that the cytokine interleukin-2 (IL-2) has boosted nTreg cell expansion with flowing immune responses to antigens. This is further validated by the observation that genetic ablation of IL-2 in TGF-βRI-deficient mice reduced the quantity of thymic nTreg cells (Liu et al., 2008) . IL-2 also promotes the development and maintenance of iTreg cells Zheng et al., 2007) . Subsequent work has showed that TGF-β signaling in T cells protects nTregs from apoptosis during thymic development by suppression of proapoptotic proteins and upregulation of the antiapoptotic protein Bcl-2 (Ouyang et al., 2010) .
Central T cell tolerance consists of diversified mechanisms, of which two main mechanisms are to induce high-affinity self-reactive T cells apoptosis in the thymus (Mathis and Benoist, 2004) and to keep monitoring escaped autoreactive T cells (Walker and Abbas, 2002) . In contrast, peripheral T cell tolerance is mainly controlled by CD4+Foxp3+ Treg cells, in which TGF-β1 plays a critical role in suppressing T-mediated autoimmunity and Treg cell development (Li et al., 2006b; Sakaguchi et al., 2008) . Mice suffer from fatal autoimmune diseases if lacking either TGF-β1 or Foxp3, the latter being the transcription factor needed for Treg cell development and function.
TGF-β signal and iTreg development
In addition to nTreg cell development in the thymus, iTreg cells can be differentiated from naive T cells and acquire the function of Foxp3 expression in peripheral tissues in vitro and in vivo (Zheng et al., 2002; Bluestone and Abbas, 2003) . It has been suggested that TGF-β-induced Foxp3 expression was mediated by the recruitment of its downstream transcription factor Smad2/3 to a Foxp3 enhancer element by distinct mechanisms. In the setting of TCR engagement, Smad3 interacts with an enhancer region of the Foxp3 gene called CNS1 (Tone et al., 2008; Zheng et al., 2010) . Smad3 also modulates Foxp3 expression by forming an enhanceosome complex along with NFATc2 and CREB at the Foxp3 promoter (Xu et al., 2010a) . Furthermore, TGF-β-induced expression of Foxp3 is partially reduced in Smad3 knockout T cells (Martinez et al., 2009 ). Smad2 does not bind directly to the CNS1 region, but it does play a role in the TGF-β-mediated iTreg induction, given that T cells lacking Smad2 have a reduced ability to upregulate Foxp3 expression (Lu et al., 2010a) . Loss of both Smad2 and Smad3 resulted in complete ablation of Foxp3 upregulation by TGF-β (Takimoto et al., 2010) , supporting a cooperative interaction between Smad2 and Smad3 in the induction of iTregs. In addition to Smad-mediated effects, TGF-β can indirectly promote Foxp3 induction by inhibiting factors that normally suppress Foxp3, such as the transcriptional repressor Gfi-1 (Zhu et al., 2009) . Otherwise, the cytokine IL-2 that derives from T cells enhances iTreg cell differentiation induced by TGF-β (Zheng et al., 2007 (Zheng et al., , 2004a , which triggers the transcription factor STAT5, and STAT5 may synergize with Smad3 for binding to the Foxp3 promoter (Burchill et al., 2007) .
Some experiments have demonstrated that when TGF-β is expressed in the microenvironment excessively, it can evoke Foxp3 expression and iTreg cell differentiation. For instance, overexpression of TGF-β1 in the pancreatic islets in nonobese diabetic mice leads to the proliferation of CD4+Foxp3+ Treg cells that prevents mice from suffering from diabetes mellitus (Peng et al., 2004) . The induction of iTreg cells in the peripheral microenvironment also may require endogenous TGF-β. Low doses of TGF-β can also induce naive T cells to differentiate to iTreg cells through stimulating steady-state dendritic cells in peripheral tissues de novo (Kretschmer et al., 2005) . The courses of this differentiation seemed to be attenuated by effector T cell expansion, costimulation with CD40 antibody agonist, or excessive extrinsic antigens. However, these polarized iTreg cells exhibit a stable phenotype and could expand in inflammation status. In DNRII-expressing mice, when the TGF-β signaling is blocked in naive T cells, the differentiation of iTreg cells is significantly reduced, and T cells manifest the enhanced expansion conversely.
Foxp3 instability in the inflammatory conditions not only affects the Treg phenotype but also compromises its function. nTreg can convert into Th1, Th2, Th17, and T follicular helper (Tfh) cells in the presence of IL-6 or TNF-α Xu et al., 2007; Zheng et al., 2008a; Tsuji et al., 2009; Lu et al., 2010a) . iTreg stability is still controversial. Some studies suggest that iTregs are unstable (Koenecke et al., 2009) , and the Treg-specific demethylated region (TSDR) in iTregs has incomplete demethylation that possibly contributes to their instability (Floess et al., 2007) . Nonetheless, recent studies have also demonstrated that iTregs are stable and functional if the appropriate protocol to generate iTregs is used . iTregs are completely resistant to Th17 conversion while nTregs are not (Zheng et al., 2008a; O'Connor et al., 2012) . In the EAE model, iTregs are sufficiently functional and even began to express the Th1 cytokine (O'Connor et al., 2012) . In the CIA model, iTregs have demonstrated superior stability and functionality to nTregs (Kong et al., 2012) . Furthermore, iTreg cells induced in vivo appear to express Foxp3 stably and display a demethylated TSDR region (Polansky et al., 2008) . Thus, further studies are required to investigate the mechanisms regulating the stability of Foxp3 induction by TGF-β in different immunological contexts.
Naive T cells in transgenic mouse models could also convert to iTreg cells when the mice were administered antigens orally (Coombes et al., 2007) . The vitamin A metabolite retinoic acid (atRA) has been attributed to this prior conversion of iTregs at the mucosal site. TGF-β-mediated induction of Foxp3 is enhanced by atRA (Benson et al., 2007) , which can be secreted by GALT DCs and macrophages to promote iTreg induction in the intestine (Coombes et al., 2007; Sun et al., 2007) , lungs (Soroosh et al., 2013) , and skin (Guilliams et al., 2010) . atRA facilitates iTreg induction by binding to regulatory elements in the Foxp3 promoter and enhancer regions, and by enhancing TGF-β-mediated histone acetylation at the Foxp3 promoter, then promoting phosphorylated Smad3 binding to the CNS1 enhancer region of the Foxp3 gene (Kang et al., 2007; Xu et al., 2010b; Lu et al., 2011) , or indirectly by inhibiting proinflammatory cytokine production by effector/memory T cells and dampening the responsiveness of T cells to proinflammatory cytokines (which normally block iTreg induction) (Hill et al., 2008; Takaki et al., 2008) . atRA also promotes the development of human iTregs and stabilizes nTreg cells in inflammatory conditions (Lu et al., 2010b Zhou et al., 2010) .
It is worth noting that when administering neutralizing TGF-β antibody or atRA receptor inhibitors, iTreg cell generation was inhibited dramatically. Nevertheless, the delivery of atRA enhanced the function of TGF-β in the preferential induction of iTreg cells (Benson et al., 2007; Coombes et al., 2007; Sun et al., 2007) . Accordingly, mucosal antigens derived from commensal flora or dietary sources without adverse effects may mainly contribute to induced peripheral immune tolerance.
Roles of TGF-β in Treg maintenance and function
Mice lacking TGF-β1 (Marie et al., 2005) or TGF-βRII on T cells (Li et al., 2006a) display marked reductions in Foxp3+ Treg numbers in the periphery, suggesting a role for TGF-β in the maintenance of Treg cells. However, repopulation of mice lacking TGF-βRII on T cells with wild-type Tregs did not prevent multiorgan inflammation (Li et al., 2006a; Marie et al., 2006) . One explanation for these results is that Foxp3+ Treg-mediated suppression of effector T cells requires TGF-β responsiveness in those cells, which has been confirmed in mice models of colitis (Fahlen et al., 2005) . In some studies, peripheral Treg numbers are diminished in the absence of TGF-β production/signaling. However, using a mouse model lacking the CNS1 enhancer of the Foxp3 gene that is required for TGF-β-mediated upregulation of Foxp3 expression and iTreg induction (Josefowicz et al., 2012b) , a study revealed that these mice did not develop the severe, early-onset multiorgan inflammation seen in mice lacking all Tregs, suggesting that nTregs are sufficient to prevent this phenotype. This conclusion is not consistent with the observation that, in older mice lacking iTregs, Th2-mediated pathology developed in the lungs and intestine, with altered bacterial species detected in the gut (Josefowicz et al., 2012b) , indicating that iTregs are important in controlling immune responses in some peripheral tissues. Thus, further work is required to definitively determine the contributions of iTregs and nTregs at mucosal surfaces and other tissues.
Although many different cell types produce TGF-β, the discovery that mice with T cell-specific Tgfb1 deficiency develop autoimmunity and exhibit early mortality around 6 months of age (Li et al., 2007) highlights the importance of T cell-derived TGF-β in the regulation of T cell tolerance. It was further demonstrated that iTreg cells are a main source of active TGF-β that contributes to producing the next generation of iTregs through a phenomenon called "infectious tolerance" and long-term immune tolerance (Horwitz et al., 2004; Zheng et al., 2004a) .
Recent work has suggested that an additional CD4+Foxp3-Treg population also has an important suppressive function and that this subset is characterized by cell surface expression of the latency-associated peptide (LAP) (da Cunha and Weiner, 2012). It is known that TGF-β needs to interact with LAP and then is released into the active form. Investigators call these cells Th3-type Tregs and they are important for the suppressive effects mediated by anti-CD3 antibody in several autoimmune diseases (da Cunha and Weiner, 2012). TGF-β has also been shown to induce expression of CD73 on activated T cells independently of Foxp3 expression, which can induce adenosine to suppress T cell proliferation (Regateiro et al., 2011) . Additionally, by costimulation with IL-27, TGF-β can drive induction of Tr1 cells, which are a Foxp3-suppressive CD4+ T cell subpopulation characterized by high expression of IL-10 ( Awasthi et al., 2007; Maynard et al., 2007) . It is unclear why Foxp3 expression does not occur in this condition and the potential role of TGF-β in regulating Foxp3-Treg subsets deserves further exploration.
Function of TGF-β in T helper cell differentiation
It has been recognized that TGF-β blocks the production of IL-2 and the expression of IL-2 receptor that inhibits the development and expansion of T helper cells (Letterio and Roberts, 1998) , and TGF-β provides costimulatory function for T cells instead when the level of IL-2 is sufficient to antagonize these blocking effects . Nonetheless, TGF-β inhibits naive CD4+ T cells' conversion to Th1 or Th2 cells but promotes naive CD4+ and CD8+ cells to differentiate to Treg cell lineages (Ludviksson et al., 2000; Zheng et al., 2004b; Ma et al., 2014) . Thus, TGF-β, as a pleiotropic cytokine, plays a vital role in effector response and tolerance in a context-dependent mechanism. TGF-β can also induce activated CD4+ and CD8+ cells to become various other T cell subsets, such as Th1, Th2, and Th9, as well as Th17 cells under certain conditions, which is explained below in detail.
Th1 and Th2 cell differentiation
TGF-β can broadly impede T cell activation by inhibiting TCR signaling, but it also inhibits specific T helper subsets by suppressing lineage-defining transcription factors, such as T-bet and GATA-3, which are critical for Th1 and Th2 cell differentiation, respectively Neurath et al., 2002) . Indeed, TGF-β signaling-deficient CD4+ T cells produce increased Th1 and Th2 cytokines . Recent work has elucidated the nonredundant roles of the transcription factors Smad2 and Smad3 in TGF-β inhibition of Th1 cell differentiation (Takimoto et al., 2010; Gu et al., 2012) . The Smad signaling pathway also mediates TGF-β inhibition of Th2 cell differentiation by inducing the transcription factor Sox4, which interferes with GATA-3 activity (Kuwahara et al., 2012) .
Th17 cell differentiation
A role for TGF-β in the induction of the Th17 lineage was established through in vitro differentiation assays and in vivo observations that mice with defective TGF-β signaling possessed fewer IL-17-producing T cells, whereas overexpression of Tgfb1 led to an increase in Th17 cells (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006) . Mechanistically, TGF-β is suggested to promote the Th17 lineage by inhibiting the differentiation of other helper subsets, as stimulation with IL-6 alone was sufficient to induce IL-17 production in CD4+ T cells lacking essential Th1 and Th2 molecules (Das et al., 2009 ). Accordingly, TGF-β enhances IL-17 production in CD4+ T cells by suppressing mediated suppression of Gfi-1 and eomesodermin, which promotes Th2-and Th1-associated cytokines, respectively (Zhu et al., 2009; Ichiyama et al., 2011) . Other environmental factors, such as IL-2, atRA, and IL-6, also influence the development of a specific lineage. For example, IL-2 and atRA promote iTregs but restrain Th17 cells, while IL-6 has an opposite role that promotes Th17 but inhibits iTreg cell development (Bettelli et al., 2006; Davidson et al., 2007; Laurence et al., 2007; Zheng et al., 2007; Lu et al., 2011) . At the molecular level, it has been shown that TGF-β can induce the same CD4+ T cells to express both Foxp3 and RORγt (the key Th17 transcription factor). As Foxp3 inhibits RORγt activity, TGF-β can favor iTreg cell development (Zhou et al., 2008) . However, TGF-β was shown to be dispensable for murine Th17 differentiation, as stimulation with IL-23, IL-6, and IL-1β was also sufficient to induce IL-17 production by CD4+ T cells (Romagnani et al., 2009; Ghoreschi et al., 2010) . These Th17 cells, but not those IL-17-producing cells cultured with TGF-β and IL-6, could induce EAE in a transfer model of disease (McGeachy et al., 2007) , because these pathogenic cells may produce little IL-10 and express high levels of T-bet (Ghoreschi et al., 2010) . Although Treg cells could provide sufficient amounts of TGF-β1 to induce in vitro Th17 differentiation (Veldhoen et al., 2006) , Treg cell-derived TGF-β1 was not required for in vivo differentiation (Gutcher et al., 2011) . This research suggests that autocrine TGF-β1 signaling is essential for in vivo Th17 differentiation. This was confirmed by mixed bone marrow chimera experiments showing that Tgfb1-deficient T cells failed to produce IL-17 even in the presence of wild-type cells (Gutcher et al., 2011) .
Th9 cell differentiation
Th9 cells are a recently discovered T helper cell lineage, which predominantly produces IL-9. Th9 cells were identified as an important regulator in respiratory tract epithelial pathogenesis and inducing EAE (Elyaman et al., 2012; Xiao et al., 2012) . It was revealed that IL-9 from mast cells recruits Treg cells to skin grafts to inhibit graft-versushost disease (Lu et al., 2006) . Nonetheless, the exact role of Th9 cells in the immune system has not been defined.
Th9 cells were initially regarded as a derivative of Th2 cells to cease the expression of IL-4 and initiate production of IL-9 that resulted from the polarization of other transcription factors such as interferon regulatory factor 4 (IRF4) and purine-rich box 1 (PU.1) (Chang et al., 2005 (Chang et al., , 2010 Veldhoen et al., 2008; Staudt et al., 2010) . However, other investigations suggest that up to 80% of the naive CD4+ T cells can be directly induced to differentiate to Th9 cells in the culture conditions of TGF-β and IL-4 when OX40 is also administrated .
TGF-β alone can promote the differentiation of Treg cells while IL-4 alone can convert to induce Th2 cells. Interestingly, the combination of TGF-β and IL-4 provides the optimal cytokine culture for Th9 cell polarization. Further study demonstrated that Th9 differentiation is complicated and identified Th9 cells as a distinctive lineage rather than Th2 and Treg cells. IL-4 triggers STAT6 and IRF4, and TGF-β triggers PU.1 and inhibits GATA3 (GATA-binding protein 3) and T-bet (T-box expressed in T cells). However, the combination of TGF-β and IL-4 finally induces only IL-9 expression without IL-4 or IL-10 ( Murphy and Reiner, 2002; Ansel et al., 2006; Perumal and Kaplan, 2011) . Furthermore, the engagement of OX40 under Treg-or Th17-converting conditions appears to block the expression of Foxp3+ or IL-17. Therefore, the function of OX40 on Th9 differentiation remains a topic for further investigation . In the conditions of TGF-β and IL-4, the transcription factors PU.1 and IRF4 have been identified as the crucial promoters in Th9 cell induction (Chang et al., 2010; Staudt et al., 2010) . Under OX40 costimulation, the cytokine IL-10 could not be detected in Th9 cells. However, without the combination of TGF-β and IL-4, OX40 signaling turns to induce Th1 and Th2 differentiation .
Th22 cell differentiation
Th22 cells have been suggested to be a new T helper cell subset, since they produce IL-22 but not IFN-γ, IL-4, and IL-17 (Duhen et al., 2009; Trifari et al., 2009 ). Th22 cells are mainly distributed to epithelial tissues and keratinocytes, and they play an important role in skin homeostasis and inflammation. The transcription factor aryl hydrocarbon receptor (AHR) is required for the development of Th22 cells (Trifari et al., 2009; Ramirez et al., 2010) and the administration of AHR increases IL-22 production and decreases IL-17 expression. Th22 cells express a high level of AHR. Th22 cells express only low or undetectable levels of transcription factors RORγt and T-bet, required in the generation of Th17 and Th1 cells (Duhen et al., 2009 ). In addition, Th22 cells also express the chemokine receptor CCR6, the skin homing receptor CCR4, and CCR10, which are culprit cytokines for skin and mucosa diseases, such as infections, autoimmune diseases, and tumors. Thus, it is likely that Th22 cells are closely associated with skin and mucosa immune homeostasis and inflammation (Duhen et al., 2009; Trifari et al., 2009) .
Recent studies also demonstrated that the level of Th22 cells and IL-22 increased in infection sites (Zheng et al., 2008b) , in inflamed intestines of IBD or CD patients (Andoh et al., 2005; Wolk et al., 2007) , and in primary tumor tissue (Jiang et al., 2011 (Jiang et al., , 2013 . Thus, it has been suggested that IL-22 and Th22 cells may be important for the pathogenesis of these skin and mucosa diseases.
Th22 and Th17 cells are identified to be crucial IL-22 producers (Duhen et al., 2009; Trifari et al., 2009) . TGF-β promotes Th17 but not Th22 differentiation, and, conversely, it suppresses Th22 differentiation (Ghoreschi et al., 2010) . Naive CD4+ T cells can differentiate into Th22 cells in the presence of cytokines IL-6 and TNF-α and this differentiation is further enhanced by the addition of IL-1β (Duhen et al., 2009) . Additionally, another study showed that Langerhans cells may also regulate Th22 cell development (Fujita et al., 2009) .
Interestingly, activated CD4+ cells still maintain the function of expressing some levels of IL-22 when cultured in Th1-, Th2-, Th17-, or Treg-conversion conditions (Eyerich et al., 2009) , although a high dose of TGF-β (5 ng/mL) can reduce the production of IL-22. Other effector cells such as CD8+ T cells and NK cells also produce IL-22; however, the level IL-22 produced is insufficient to exert their functional activity in immune responses. It still remains unclear how the regulatory factors and transduction mechanism are involved in Th22 cell differentiation. Moreover, the relationships among Th22 cells and other IL-22-producing cells in local immune responses need to be further investigated.
Roles of miRNAs in TGF-β-dependent T cells' differentiation and function
miRNAs are short, noncoding RNAs that regulate gene expression and mainly cause gene silencing via degradation of target mRNAs and inhibition of translation (Makeyev et al., 2008) . Numerous individual miRNAs were identified as important regulators in phenotypic stability, differentiation, and plasticity of T cells inducing Treg cells (Baumjohann et al., 2013) . As a result, miRNAs modify many cellular signaling pathways and regulate autoimmune disease processes (Ambros, 2004; Bartel, 2004) .
One recent study indicated that the differential expression of miRNAs may affect naive CD4 T cells' differentiation into iTregs by reducing TGFβR1 and SMAD4 and then altering the TGF-β signal pathway in patients with multiple sclerosis (Severin et al., 2016.) . In addition, the combination of these miRNAs, such as miR-141/500/let-7b, exhibited significant synergistic effects on the decrease of iTreg development (Severin et al., 2016.) . Nevertheless, these miRNAs only limit Treg development, not IL-10 production and function of iTreg cells.
The correlation between TGF-β and miRNAs also affects pathogenic cells. For example, the expression of miR-323-3p in IL-22/IL-17-producing T cells increased in patients with asthma and atopic dermatitis. Study has demonstrated that miR-323-3p may suppress STAT3 mRNA, whereas TGF-β may promote Th22 cells (Kärner et al., 2016) . Upon accumulation of IL-22 and IL-17, miR-323-3p produced by T cells inhibits the expression of SMAD2, SMAD3, and STAT3, resulting in diminished production of IL-22. SMAD2, SMAD3, CDKN1B, and STAT3 are important transcription factor from the TGF-β signaling pathway. SMAD2 and SMAD3 have been demonstrated to inhibit the development of Th17 cells and are subject to TGF-β receptor-mediated phosphorylation and subsequent activation (Rubtsov et al., 2007; Lu et al., 2010a) . Thus, targeting some specific miRNAs may have a potential to regulate the balance between Treg and T effector cell with clinical benefits.
It has been noted that the targeting of miRNAs as therapeutic agents has several problems. For instance, these miRNAs might regulate other genes outside of the TGF-β signaling pathway and cause severe side effects. However, since miRNAs are easily quantified from cells, tissue, and blood, they may at least serve as appropriate biomarkers in evaluating the onset, development, therapeutic responses, and progress of many autoimmune diseases.
Conclusion
It seems for now that maintaining the balance among Treg cells and other T helper cells is a dynamically regulated and context-dependent process that allows the immune system to appropriately initiate and resolve immune responses to invading pathogens and tumors, while preventing autoimmunity and limiting collateral tissue damage and immunopathology. Treg homeostasis is governed by a number of factors, ranging from cytokines, TCR, and costimulatory signaling to APC. Among these factors, TGF-β is vital to induce Treg development and function, and also to affect the differentiation of other T helper subsets through regulation factors including miRNA (miR-141/500/let-7b/miR-323-3p) and TGF-β downstream pathways (Smad and non-Smad pathways) (Figure) . These mechanisms will facilitate the finding of a promising approach for treating chronic infection, autoimmunity, and cancers. Similarly, these strategies also help to control the side effects that can arise from the presence of more or fewer Treg or Th cells. Although targeting miRNAs or TGF-β downstream pathways as therapeutic agents may involve many problems including severe side effects, they at least can serve as biological biomarkers in many autoimmune diseases. Nonetheless, further studies are required to determine the ways to manipulate TGF-β signals for the treatment of relevant diseases in the clinic. Function of TGF-β in the development of Treg cells and T helper cells. TGF-β induces stimulatory or inhibitory effects in T cells by triggering numerous Smad-dependent or -independent signaling pathways in a context-dependent way. TGF-β protects nTregs from apoptosis during development by upregulation of the antiapoptotic protein Bcl-2. TGF-β is essential for iTreg differentiation by the interaction between Smad2 and Smad3 and the activation of Foxp3 gene expression. Some miRNAs such as miR-141/500/let-7b may affect the naive CD4 T cells' differentiation into iTregs by reducing TGF-βR1 and SMAD4. TGF-β suppresses transcription factors, T-bet, and cytokine eomesodermin, which are critical for Th1 cell differentiation. TGF-β also inhibits Th2 cell differentiation by inducing the transcription factor Sox4 and interfering with GATA-3 activity. The combination of TGF-β and IL-4 when OX40 is also administrated provides the optimal cytokine culture for Th9 cell polarization. IL-4 triggers STAT6 and IRF4, and TGF-β triggers PU.1 and inhibits GATA3 and T-bet. TGF-β suppresses Th22 differentiation and the production of IL-22. miR-323-3p inhibits the expression of SMAD2, SMAD3, and STAT3, which results in diminished production of IL-22.
